Drugs / Ertugliflozin 10 mg
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01999218 | Dec 2013 → Apr 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ertugliflozin 10 mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01999218 ↗ |
| Action | Inhibit | “The sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin” PMID 32372382 ↗ May 2020 |
| Route | Oral | “Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.” NCT01999218 ↗ |